Loading clinical trials...
Loading clinical trials...
Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia : a Multicenter, Parallel-group, Open-label, Randomized Controlled Trial
Conditions
Interventions
Combined use of a respiratory broad panel multiplex PCR and procalcitonin
Usual antibiotic treatment
Locations
1
France
Intensive care department-Hospital Tenon
Paris, France
Start Date
April 20, 2020
Primary Completion Date
December 20, 2020
Completion Date
June 23, 2021
Last Updated
August 3, 2021
NCT07409727
NCT07186933
NCT06169514
NCT06092008
NCT07298889
NCT06750536
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions